[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박수용 | - |
dc.contributor.author | 임민영 | - |
dc.contributor.author | 여인구 | - |
dc.contributor.author | 하민수 | - |
dc.contributor.author | 김주승 | - |
dc.contributor.author | 이지원 | - |
dc.contributor.author | 정영걸 | - |
dc.contributor.author | 권오상 | - |
dc.contributor.author | 김연수 | - |
dc.contributor.author | 최덕주 | - |
dc.contributor.author | 김주현 | - |
dc.date.available | 2020-02-29T04:46:06Z | - |
dc.date.created | 2020-02-11 | - |
dc.date.issued | 2012-11 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16023 | - |
dc.description.abstract | A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9% (290/326) and 64.4% (491/762) respectively and 88.8% (135/152), and 79.4% (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3% (1,981/3,860) and 42.4% (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한소화기학회 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.title | [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis]. | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.4166/kjg.2012.60.5.306 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.60, no.5, pp.306 - 314 | - |
dc.identifier.kciid | ART001713027 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-84887522117 | - |
dc.citation.endPage | 314 | - |
dc.citation.startPage | 306 | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 60 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | 박수용 | - |
dc.contributor.affiliatedAuthor | 임민영 | - |
dc.contributor.affiliatedAuthor | 여인구 | - |
dc.contributor.affiliatedAuthor | 하민수 | - |
dc.contributor.affiliatedAuthor | 김주승 | - |
dc.contributor.affiliatedAuthor | 이지원 | - |
dc.contributor.affiliatedAuthor | 정영걸 | - |
dc.contributor.affiliatedAuthor | 권오상 | - |
dc.contributor.affiliatedAuthor | 김연수 | - |
dc.contributor.affiliatedAuthor | 최덕주 | - |
dc.contributor.affiliatedAuthor | 김주현 | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | C형간염 | - |
dc.subject.keywordAuthor | 페그인터페론 | - |
dc.subject.keywordAuthor | 리바비린 | - |
dc.subject.keywordAuthor | 통합분석 | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | Peginterferon | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.subject.keywordAuthor | Pooled analysis | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | macrogol derivative | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | peginterferon alpha2b | - |
dc.subject.keywordPlus | recombinant protein | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | ethnology | - |
dc.subject.keywordPlus | factual database | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | genotype | - |
dc.subject.keywordPlus | hepatitis C | - |
dc.subject.keywordPlus | Hepatitis C virus | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | meta analysis | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Databases, Factual | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Genotype | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Interferon-alpha | - |
dc.subject.keywordPlus | Polyethylene Glycols | - |
dc.subject.keywordPlus | Recombinant Proteins | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.